Cardiovascular Risk and HRT: A Meta-Analysis Finds the Answer Depends on When You Start

This systematic review and meta-analysis, published in Scientific Reports, examined 26 randomized controlled trials and 47 observational studies to assess the cardiovascular effects of menopausal hormone therapy. The findings are more complex than the simple "HRT is bad for your heart" narrative that dominated clinical thinking after the WHI. Both study types consistently identified increased risks of venous thromboembolism with hormone therapy. RCTs also showed an increased risk of stroke. However, observational studies reported a decreased risk of myocardial infarction — a discordance that highlights the importance of population selection, timing, and formulation.

The analysis supports what subsequent research has continued to confirm: the cardiovascular risk profile of hormone therapy is not monolithic. Age at initiation, years since menopause, type of estrogen (oral versus transdermal), type of progestogen (synthetic versus micronized progesterone), and route of administration all modulate risk. Women who begin therapy closer to menopause and use transdermal formulations appear to have a more favorable cardiovascular profile. Meanwhile, a separate 2024 analysis of 33 RCTs involving over 44,000 postmenopausal women found no significant overall difference in all-cause death or cardiovascular events between hormone therapy and placebo — though stroke and VTE risks persisted. The story is one of nuance, not blanket risk.

Why This Matters

Cardiovascular disease remains the leading cause of death in women, and the relationship between menopause, estrogen loss, and heart health is not optional knowledge — it is foundational. The problem is that the clinical decision to use or avoid hormone therapy requires individualized risk assessment: age, time since menopause, family history, blood pressure trends, lipid panels, body composition, and symptom severity all factor in. A health monitoring platform that captures these variables longitudinally — and flags when a woman's profile shifts — gives both patient and clinician the information needed to make this decision proactively rather than reactively. Cardiovascular risk does not announce itself. It accumulates, and tracking is how you see it before it becomes an event.